Skip to main content

Table 1 Baseline characteristics of study participants at enrollment

From: Plasmodium falciparum gametocyte dynamics after pyronaridine–artesunate or artemether–lumefantrine treatment

 

Pyronaridine–artesunate

Artemether–lumefantrine

N

85

75

Malea

54.1 (46/85)

49.3 (37/75)

Age (years)b

7.0 (4.2–9.0)

6.0 (3.4–9.8)

Hb (g/dL)c

11.8 (11.4–12.2)

11.7 (11.2–12.2)

Temperature (°C)c

37.6 (37.4–37.9)

37.4 (37.1–37.7)

Fever (temperature > 37.5 °C)a

55.3 (47/85)

48.0 (36/75)

Asexual parasite density (p/µl)b

28,800 (12,000–68,640)

29,280 (12,000–67,680)

Gametocyte prevalence—microscopya

2.35 (2/85)

5.33 (4/75)

Gametocyte prevalence—QT-NASBAa

95.3 (81/85)

94.7 (71/75)

Gametocyte density—QT-NASBA (p/µl)b

3.23 (0.68–18.1)

6.36 (1.19–22.2)

Gametocyte prevalence—Pfs25 qRT-PCRa

97.7 (83/85)

100 (75/75)

Gametocyte density—Pfs25 qRT-PCR (p/µl)b

2.88 (0.85–5.24)

1.94 (0.77–5.35)

Gametocyte prevalence—PfMGET qRT-PCRa

35.3 (30/85)

41.3 (31/75)

Gametocyte density—PfMGET qRT-PCR (p/µl)b

0.94 (0.11–14.1)

0.48 (0.21–10.1)

  1. Data are: a Percentage % (n/N), b Median and IQR or c Mean and 95% CI